1. Dong, Yuxuan, Jin, Fengbo, Wang, Jing, Xia, Leiming, Yang, Mingzhen. . SFXN3 is Associated with Poor Clinical Outcomes and Sensitivity to the Hypomethylating Therapy in Non-M3 Acute Myeloid Leukemia Patients. In Current gene therapy, 23, 410-418. doi:10.2174/1566523223666230724121515. https://pubmed.ncbi.nlm.nih.gov/37491851/
2. Jin, Fengbo, He, Limei, Wang, Jing, Zhang, Yu, Yang, Mingzhen. 2024. SFXN3 is a Prognostic Marker and Promotes the Growth of Acute Myeloid Leukemia. In Cell biochemistry and biophysics, 82, 2195-2204. doi:10.1007/s12013-024-01326-5. https://pubmed.ncbi.nlm.nih.gov/38877336/
3. Amorim, Inês S, Graham, Laura C, Carter, Roderick N, Wishart, Thomas M, Gillingwater, Thomas H. 2017. Sideroflexin 3 is an α-synuclein-dependent mitochondrial protein that regulates synaptic morphology. In Journal of cell science, 130, 325-331. doi:10.1242/jcs.194241. https://pubmed.ncbi.nlm.nih.gov/28049716/
4. Chen, Kailin, Gong, Sha, Fang, Xueliang, Li, Yingqin, Ma, Jun. 2022. Non-coding RNA-mediated high expression of SFXN3 as a prognostic biomarker associated with paclitaxel resistance and immunosuppressive microenvironment in head and neck cancer. In Frontiers in immunology, 13, 920136. doi:10.3389/fimmu.2022.920136. https://pubmed.ncbi.nlm.nih.gov/36159813/
5. Chen, Bo, Aredo, Bogale, Ding, Yi, Beutler, Bruce, Ufret-Vincenty, Rafael L. 2020. Forward genetic analysis using OCT screening identifies Sfxn3 mutations leading to progressive outer retinal degeneration in mice. In Proceedings of the National Academy of Sciences of the United States of America, 117, 12931-12942. doi:10.1073/pnas.1921224117. https://pubmed.ncbi.nlm.nih.gov/32457148/
智鼠故事 
